Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Decreased by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at Zacks Research reduced their Q1 2025 EPS estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday, October 8th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of ($0.16) per share for the quarter, down from their previous forecast of ($0.15). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q2 2025 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.25) EPS and FY2026 earnings at ($0.02) EPS.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC lowered their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Bank of America lowered shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $2.90 to $2.50 in a research report on Thursday, June 20th. StockNews.com raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, October 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Trading Up 4.2 %

Shares of NASDAQ ESPR opened at $1.97 on Friday. The firm has a market cap of $373.24 million, a P/E ratio of -1.99 and a beta of 1.00. The business’s 50 day moving average is $1.82 and its 200-day moving average is $2.18. Esperion Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.10. The company had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds have recently bought and sold shares of ESPR. BOKF NA bought a new stake in shares of Esperion Therapeutics during the 2nd quarter worth $26,000. Xponance Inc. bought a new position in shares of Esperion Therapeutics in the second quarter worth about $28,000. CVI Holdings LLC acquired a new stake in shares of Esperion Therapeutics in the 1st quarter valued at approximately $37,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Esperion Therapeutics during the 1st quarter valued at approximately $50,000. Finally, National Bank of Canada FI increased its position in Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,225 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.